Patrick Daly
Articles by Patrick Daly
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
Lactate dehydrogenase level was pinpointed as a significant predictor of thromboembolism and mortality.
Dr. Naik gives an in-depth look at the ASH Hematology-Focused Fellowship Training Program and its goals.
Dr. Restrepo discusses coagulation and issues in coagulopathy risk screening in patients who have venous malformations.
Konstanze Döhner, MD, met to discuss the background and ongoing progress of the EHA Lighting the Flame program.
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.